Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL346 in Diabetic Kidney Disease
NCT04419467Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Sep 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of reflocibart in diabetic kidney disease (DKD), sponsored by CSL Limited. Started Sep 2020; status: completed.
02
Drugs
reflocibart
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT04419467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419467.